ClinicalTrials.gg
CompletedNCT07748585Updated Sep 24, 2026

Effect of Titanium-Prepared Platelet-Rich Fibrin and Low-Level Laser Therapy on Postoperative Morbidity After Mandibular Third Molar Surgery

An interventional study of Titanium-Prepared Platelet-Rich Fibrin (T-PRF) and Low-Level Laser Therapy (LLLT) in Impacted Mandibular Third Molar Extraction, sponsored by Cyprus Health and Social Sciences University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 31 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Cyprus Health and Social Sciences University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 31 Years
Sex
All
01

Study summary

This randomized double-blind clinical trial aims to evaluate the effects of titanium-prepared platelet-rich fibrin (T-PRF), low-level laser therapy (LLLT), and their combination on postoperative outcomes following surgical extraction of impacted mandibular third molars. Sixty patients will be randomly allocated to one of four parallel groups: T-PRF, LLLT, T-PRF plus LLLT, or control. The primary outcomes include postoperative pain assessed using a visual analogue scale (VAS), analgesic consumption, postoperative swelling and trismus. The findings may help identify effective approaches for improving postoperative recovery after mandibular third molar surgery.

02

Conditions studied

  • Impacted Mandibular Third Molar Extraction
03

In context

Lead sponsor

Cyprus Health and Social Sciences University is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 31 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults requiring surgical extraction of a unilateral vertically impacted mandibular third molar.
  • Healthy individuals ().
  • Ability to provide written .
  • Willingness to attend all follow-up visits.

Exclusion criteria

Exclusion Criteria:

  • Systemic disease affecting wound healing.
  • Pregnancy or lactation.
  • Active infection or acute pericoronitis.
  • Long-term opioid use.
  • Smoking and alcohol use.
  • Known allergy to study medications.
  • Previous radiotherapy to the head and neck region
  • Inability to attend follow-up visits.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • No intervention
    Control

    Participants underwent standard surgical extraction of an impacted mandibular third molar without T-PRF placement or active low-level laser therapy.

  • Experimental
    T-PRF

    Participants received titanium-prepared platelet-rich fibrin (T-PRF) placed into the extraction socket immediately after mandibular third molar surgery.

    Procedure: Titanium-Prepared Platelet-Rich Fibrin (T-PRF)

  • Experimental
    LLLT

    Participants received low-level laser therapy immediately after surgery and once daily for the following two postoperative days.

    Device: Low-Level Laser Therapy (LLLT)

  • Experimental
    T-PRF + LLLT

    Participants received titanium-prepared platelet-rich fibrin (T-PRF) placed into the extraction socket together with low-level laser therapy immediately after surgery and once daily for the following two postoperative days.

    Procedure: Titanium-Prepared Platelet-Rich Fibrin (T-PRF) · Device: Low-Level Laser Therapy (LLLT)

Interventions

  • ProcedureTitanium-Prepared Platelet-Rich Fibrin (T-PRF)

    Titanium-prepared platelet-rich fibrin (T-PRF) was prepared from autologous blood and placed into the extraction socket immediately after mandibular third molar surgery.

  • DeviceLow-Level Laser Therapy (LLLT)

    Low-level laser therapy was applied using a 650 nm diode laser (25 mW) immediately after surgery and once daily for the following two postoperative days.

06

What researchers measure

Primary outcomes

  1. Postoperative Pain

    Postoperative pain assessed using a 100-mm Visual Analog Scale (VAS).

    Time frame: Postoperative Days 1, 2, 3, and 7

  2. Analgesic Consumption

    Number of analgesic tablets consumed after surgery.

    Time frame: Postoperative Days 1, 2, 3, and 7

  3. Facial Swelling

    Postoperative facial swelling will be evaluated using standardized linear facial measurements. Three distances will be measured with a flexible measuring tape: tragus to the corner of the mouth (Tragus-Commissure), tragus to the soft-tissue pogonion (Tragus-Pogonion), and lateral canthus of the eye to the mandibular angle (Lateral Canthus-Gonion). The sum of the three measurements (in centimeters) will be recorded for each participant. Higher values indicate greater postoperative facial swelling.

    Time frame: Preoperative baseline and Postoperative Days 1, 2, 3, and 7

  4. Maximum Interincisal Mouth Opening (Trismus)

    Postoperative trismus will be evaluated by measuring the maximum interincisal mouth opening using a calibrated caliper. The distance (in millimeters) between the incisal edges of the maxillary and mandibular central incisors during maximum mouth opening will be recorded for each participant. Lower values indicate greater postoperative trismus.

    Time frame: Preoperative baseline and Postoperative Days 1, 2, 3, and 7

07

Study locations

1 site
  • Cyprus Health and Social Sciences University, Faculty of Dentistry
    Güzelyurt, Güzelyurt 99700, Turkey (Türkiye)
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Jun 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2026
First posted
Aug 5, 2026
StartActual
Nov 27, 2025
Primary completionActual
Jun 22, 2026
CompletionActual
Jun 29, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07748585
Lead sponsor
Cyprus Health and Social Sciences University
Responsible party
Salih Alpcan (Principal Investigator, Cyprus Health and Social Sciences University) — Principal investigator
First posted
Aug 5, 2026
Start date
Nov 27, 2025
Primary completion
Jun 22, 2026
Completion
Jun 29, 2026
Last update
Sep 24, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion